Patricia McGarry, MD
Family Medicine · Benton, ARNPI 1891816153
Payments from drug & device makers
Across 255 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amarin Pharma, Inc.$340
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$251
- Abbott$181
- Avanir Pharmaceuticals, Inc.$179
- GSK$177
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,70398%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $1,009 |
| Amarin Pharma, Inc. | 23 | $340 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $251 |
| Abbott | 10 | $181 |
| Avanir Pharmaceuticals, Inc. | 8 | $179 |
| GSK | 13 | $177 |
| Lilly USA, LLC | 10 | $161 |
| Lundbeck LLC | 8 | $143 |
| Merck | 9 | $137 |
| Pfizer | 9 | $137 |
| Amgen | 8 | $135 |
| Otsuka America Pharmaceutical, Inc. | 8 | $135 |
| Axsome Therapeutics, Inc. | 5 | $114 |
| AstraZeneca | 6 | $107 |
| Supernus Pharmaceuticals, Inc. | 4 | $75 |
| Astellas Pharma US Inc | 3 | $59 |
| Eisai Inc. | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Novo Nordisk | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| MDD US Operations, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,765 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $58,817 |
| RexultiBrexpiprazole | 33 | $50,416 |
| FarxigaDapagliflozin Propanediol | 44 | $46,700 |
| OzempicSemaglutide | 30 | $40,665 |
| EliquisApixaban | 40 | $28,119 |
| MounjaroTirzepatide | 25 | $26,700 |
| TrulicityDulaglutide | 15 | $23,386 |
| JanuviaSitagliptin Phosphate | 21 | $23,167 |
| LinzessLinaclotide | 26 | $17,257 |
| MovantikNaloxegol Oxalate | 35 | $15,525 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $14,271 |
| GemtesaVibegron | 28 | $13,888 |
| QuliptaAtogepant | 12 | $13,186 |
| BelsomraSuvorexant | 24 | $12,673 |
| TradjentaLinagliptin | 17 | $12,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $177 | $71,89482 claims |
| AstraZenecaFarxiga, Symbicort | $107 | $53,76260 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $135 | $50,41633 claims |
| MerckJanuvia, Janumet, Belsomra | $137 | $50,11067 claims |
| Lilly USA, LLCMounjaro, Trulicity | $161 | $50,08640 claims |
| Novo NordiskOzempic | $18 | $40,66530 claims |
| AbbVieLinzess, Qulipta, Synthroid | $1,009 | $34,14387 claims |
| PfizerEliquis | $137 | $28,11940 claims |
| Boehringer IngelheimTradjenta | $18 | $12,37617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Benton
- Mark AlbeyBenton$58K
- Jared DixonBenton$13K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.